Zafgen Donates Hyperphagia Questionnaire to FPWR for Use in Clinical Trials

zafgen-donates-hyperphagia-questionnaire-to-fpwr-for-use-in-clinical-trials.jpgZafgen, Inc., has donated its Hyperphagia Questionnaire for Clinical Trials (HQ-CT) instrument to FPWR to help enable the development of potential therapies for Prader-Willi syndrome.

The HQ-CT is derived from a well-established, caregiver-reported questionnaire initially developed by Dr. Elisabeth Dykens and her team at Vanderbilt University that provides an assessment of the food-seeking behaviors common among individuals with PWS, known as hyperphagia. The instrument has been validated in multiple clinical trials and is designed to evaluate a potential drug candidate’s impact on those food-seeking behaviors.

“We are extremely grateful for this donation,” said Theresa Strong, Ph.D., Director of Research Programs for FPWR. “Zafgen has leveraged its experience in PWS drug development to establish the HQ-CT as the new standard for assessing how potential therapies may impact hyperphagia. We look forward to sharing this PWS-specific study instrument with our research community.”

Providing Researchers with a Validated Tool

“Our goal with this donation is to ensure that researchers have access to this validated tool to support their ongoing and future clinical work in PWS,” said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen. “FPWR is uniquely positioned to help advance the development of PWS therapies, and we are hopeful that our HQ-CT instrument will be of value to those working to better understand and address the challenges facing people with PWS.” 

How to Access the Questionnaire

Researchers interested in gaining access to the HQ-CT should contact FPWR.

About Zafgen

Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway.

Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Its lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.

For updated information on PWS clinical trial opportunities and to sign up for a monthly PWS Clinical Trial Alert, visit the PWS Clinical Trials page.PWS Clinical Trials

Topics: News

Susan Hedstrom

author-image

Susan Hedstrom is the Executive Director for the Foundation for Prader-Willi Research. Passionate about finding treatments for PWS, Susan joined FPWR in 2009 shortly after her son, Jayden, was diagnosed with Prader-Willi Syndrome. Rather than accepting PWS as it has been defined, Susan has chosen to work with a team of pro-active and tireless individuals to accelerate PWS research in order to change the natural history of PWS. Inspired by her first FPWR conference and the team of researchers that were working to find answers for the syndrome, she hosted her first One SMALL Step walk in 2010 and began the development of the One SMALL Step walk program which now raises over $1.5 million a year for PWS research.

PWS Blog Subscribe